The fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers may include corporate or other business entities in which a sovereign or governmental agency or entity may have, indirectly or directly, an interest, including a majority or greater ownership interest.
Research context
AB Corporate Bond ETF appears in PyInvesting’s ETF catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
EyeGate Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 25.8% below its 200 day moving average.
From a valuation standpoint, the stock is 41.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1893.6.
EyeGate Pharmaceuticals, Inc's total revenue rose by inf% to $12K since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 33.1% to $-2M since the same quarter in the previous year.
Based on the above factors, EyeGate Pharmaceuticals, Inc gets an overall score of 3/5.